Francesca Jackson-Spence, Clinical Research Fellow in Genitourinary oncology at Barts Cancer Institute, shared a post on LinkedIn:
“So proud that DISCUS, the trial that I have been working on for 5 years is POSITIVE.
DISCUS is a randomised phase II, investigator-led study comparing 3vs 6 cycles of chemo in advanced urothelial cancer.
Today we have shown the result of the trial: 3 cycles of chemotherapy followed by maintenance avelumab is superior to 6 cycles of chemo on patients Quality of Life.
Published in Annals of Oncology today and presented at ESMO today in Berlin.
A big thank you to the whole team at Bart’s Centre for Experiemental Cancer Medicine, QMUL and all our colleagues in Spain and France who recruited into the study.”
Title: Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial
Authors: T. Powles, S.A. Hussain, M.A. Climent, I.G. Carbonero, J. Molina-Cerrillo, J. Puente, P. Borrega, J. Malik, L-M Dourthe, R. Jones, D. Castellano, I. Durán, Y. Loriot, G. Priyadarshini, B. Szabados, F. Jamal, Y.Q. Wang, N. Kotriwala, F. Jackson-Spence, C. Ackerman, E. Grande
You Can Also Read:
ESMO 2025 Day 1 Highlights Not to Miss
POTOMAC Trial at ESMO 2025: Durvalumab Plus BCG Improves Outcomes in High-Risk NMIBC
ESMO Announces the 2025 Society Award Winners
